These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36450264)

  • 21. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
    Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
    Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
    N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non
    Parfrey PS; Burke SK; Chertow GM; Eckardt KU; Jardine AG; Lewis EF; Luo W; Matsushita K; McCullough PA; Minga T; Winkelmayer WC
    Kidney Med; 2023 Jul; 5(7):100667. PubMed ID: 37427292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
    Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
    Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T
    Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
    Nangaku M; Kondo K; Takabe S; Ueta K; Tandai T; Kawaguchi Y; Komatsu Y
    Ther Apher Dial; 2022 Feb; 26(1):45-54. PubMed ID: 34115437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.
    Nangaku M; Ueta K; Nishimura K; Sasaki K; Hashimoto T
    Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
    Haase VH; Chertow GM; Block GA; Pergola PE; deGoma EM; Khawaja Z; Sharma A; Maroni BJ; McCullough PA
    Nephrol Dial Transplant; 2019 Jan; 34(1):90-99. PubMed ID: 29672740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
    Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease.
    Al Raisi F; Al Salmi I; Kamble P; Al Shehri M; Shaheen FA
    Saudi J Kidney Dis Transpl; 2016; 27(6):1182-1187. PubMed ID: 27900963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.
    Agarwal AK
    Expert Opin Drug Saf; 2009 Mar; 8(2):145-53. PubMed ID: 19309243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
    Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Safety and Efficacy of JR-131, a Biosimilar of Darbepoetin Alfa, in Japanese Patients With Renal Anemia Undergoing Hemodialysis: Phase 3 Prospective Study.
    Nishi S; Yamada M; Tsuruya K; Masakane I; Nakamoto H
    Ther Apher Dial; 2020 Apr; 24(2):136-145. PubMed ID: 31304637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JR-131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double-Blinded, Parallel-Group Phase 3 Study.
    Nishi S; Yamada M; Tsuruya K; Masakane I; Nakamoto H
    Ther Apher Dial; 2020 Apr; 24(2):126-135. PubMed ID: 31325212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India.
    Mazahir R; Anand K; Pruthi PK
    Eur J Pediatr; 2023 Jan; 182(1):101-109. PubMed ID: 36220980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Sulowicz W; Schömig M; Esposito C; Reusch M; Young J; Csiky B
    Adv Ther; 2021 Oct; 38(10):5345-5360. PubMed ID: 34523074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.